Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 2Phase 1/2 2

Status

Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1Genitourinary 1

Conditions

Pancreatic Neoplasms 5Colorectal Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Triple Negative Breast Neoplasms 2Ovarian Neoplasms 2Neoplasms 2Lymphoma, Non-Hodgkin 2Lymphoma 2Leukemia, Myeloid, Acute 2Leukemia, Lymphocytic, Chronic, B-Cell 2Carcinoma, Transitional Cell 2Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Recurrence 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Non-Muscle Invasive Bladder Neoplasms 1Neoplasms, Plasma Cell 1Neoplasm, Residual 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Melanoma 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lung Neoplasms 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Head and Neck Neoplasms 1Endometrial Neoplasms 1Colonic Neoplasms 1

Interventions

pembrolizumab 44Nivolumab 29Gemcitabine 28Paclitaxel 19Cisplatin 18Ipilimumab 15Carboplatin 14Cyclophosphamide 13Capecitabine 12Dexamethasone 10Bevacizumab 10cemiplimab 9Irinotecan 9Docetaxel 9Albumin-Bound Paclitaxel 9130-nm albumin-bound paclitaxel 9spartalizumab 8Pemetrexed 8Sorafenib 7Rituximab 7Cetuximab 7fludarabine 6Temozolomide 6Taxes 6Radiotherapy 6Leucovorin 6Fluorouracil 6Azacitidine 6Ascorbic Acid 6lenvatinib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Neoplasms × ALT-803 × Clear all
NCT02138734 2026-03-31

A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer

ImmunityBio, Inc.

Phase 1/2 Active not recruiting
369 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Neoplasms

NCT02384954 2024-07-03

QUILT-3.002: N-803 in Patients With Relapse/Refractory iNHL in Conjunction With Rituximab

Altor BioScience

Phase 1/2 Terminated
43 enrolled 15 charts
LymphoidOther hematologic neoplasm

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Neoplasms, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone

Data powered by HemOnc (CC BY 4.0) Colophon âš¡